A recent review published in eGastroenterology discusses recent advancements in understanding alcohol-associated liver ...

Liver fibrosis is characterized by the excessive accumulation of extracellular matrix components, leading to scarring and impaired liver function. Traditionally linked to viral infections, alcohol ...

A newly published review in eGastroenterology compiles recent research on alcohol-associated liver disease (ALD), offering an overview of its pathogenesis and efforts to better understand this ...

The Company plans to nominate a development candidate for its liver fibrosis program in the first quarter of 2025, reflecting its expertise in macrophage biology and fibrotic diseases.

Macrophages work alongside neutrophils to ... and transforming growth factor-beta (TGF-β), leading to liver fibrosis. Alcohol stimulates HSCs to produce 2-arachidonoylglycerol (2-AG), which ...

Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to ...

Read the full article. 1. Pulmonary Fibrosis, Macrophage Research Jumped Since 2020 This year’s top article reviewed research from 1990-2023, highlighting a steady increase in literature about ...

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced a strategic realignment of its resources, discontinuing ...

Resources realigned to focus primarily on in vivo macrophage engineering platform ... CAR-M oncology programs as well as our internal liver fibrosis program underscore the potential to ...

EMERALD, a Phase 1/2 study of multi-dose engineered macrophages to treat end-stage liver disease (ESLD), will be the first time engineered macrophages are used to potentially reverse fibrosis. The ...

EDINBURGH, Scotland and LONDON, Dec. 10, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering ...